PRQR News

ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026

ProQR to Participate in Upcoming Investor Conferences in September 2026

ProQR Announces Second Quarter 2026 Operating and Financial Results

ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement

ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform

ProQR Announces First Quarter 2026 Operating and Financial Results

ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform

ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026

ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors

ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event